Fourier Intelligence

A rehabilitation-robotics specialist pivoting to humanoid care-bots on investor capital, with teleoperation doing the work that marketing attributes to autonomy

---

How to Read This Report

This report separates four categories of statement throughout. Readers should weight them accordingly.

Inline citations use bracketed numerals keyed to the numbered source list in §14. Only sources present in the research dossier are cited. Where the dossier is thin, the report says so plainly.

---

01Executive Overview

Fourier Intelligence (傅利叶智能) is a Shanghai-based robotics company with a genuine, decade-long track record in neurorehabilitation devices and a newer, heavily marketed humanoid robot programme that has attracted substantial venture capital but has not yet demonstrated autonomous task execution in independent conditions. That distinction matters enormously for any investor, customer, or technology partner trying to assess where the company actually stands in 2026.

The company was founded by Gu Jie (Alex Gu) and built its initial reputation on exoskeleton and rehabilitation hardware — the Motus-series devices and the RehabHub platform — which serve clinical settings and have verifiable commercial deployments ¹⁵. That foundation is real, and it differentiates Fourier from the many humanoid-first startups that have no prior hardware revenue at all.

The humanoid programme, centred on the GR-3 (and its cosmetically distinct GR-3C variant) and the earlier GR-2, is where the company's narrative has expanded most aggressively. The GR-3 is a 165 cm, 71 kg robot with 55 joints, dual hot-swappable batteries, and a stated three-hour runtime ². It is positioned as a care-bot and social companion for children and seniors. The official product page lists whole-body teleoperation as a primary operational feature ². That single fact is the most important sentence in this report: the robot's own specification sheet confirms that a human operator drives the machine. Independent evidence of the GR-3 performing care or service tasks without a human in the loop does not exist in the public record as of this report's coverage date.

Fourier has raised approximately $62 million in a SoftBank Vision Fund-led Series D ⁵⁸ and a further approximately $123 million (800 million yuan) in a Series E announced in January 2025 ⁹. Total disclosed funding across all rounds exceeds $185 million by the most reliable sourced figures, making it one of the better-capitalised humanoid startups in China. Valuation estimates from pre-IPO secondary platforms are in the range of $147 million ³, though such figures from single commercial platforms carry low confidence and likely lag the most recent funding round.

EDITORIAL INFERENCE: The funding trajectory suggests investors are betting on the convergence of Fourier's rehabilitation expertise with the broader humanoid wave, rather than on demonstrated autonomous performance today. The company is in a transitional phase: commercially real in rehabilitation, commercially early in humanoid, and technically unverified in the autonomous-operation claims that its marketing implies.

The sections that follow examine each dimension of that picture in detail.

Latest news

This module is being compiled — no data to show yet.

---

02The Fourier Intelligence Story

Origins in Rehabilitation Engineering

Fourier Intelligence was founded in Shanghai with a focus that was, by the standards of the current humanoid frenzy, unusually grounded: clinical neurorehabilitation. The company's early product work centred on robotic exoskeletons and assistive devices for patients recovering from stroke, spinal cord injury, and other neurological conditions ¹⁵. This is a domain with genuine regulatory complexity, clinical validation requirements, and institutional procurement cycles — a harder commercial environment than consumer robotics, and one that builds real engineering discipline around human-robot physical interaction.

VERIFIED: The company's headquarters are in Shanghai, China ¹⁵⁸. The founder and CEO is Gu Jie, also known as Alex Gu, named directly in the Series D investor announcement ⁸. The rehabilitation product line, marketed under the Motus brand and unified through the RehabHub platform, is confirmed by multiple independent sources including the Robot Report and the Prosperity7 investor announcement ⁵⁸.

The precise founding date is not confirmed in the available dossier. UNKNOWN: Year of incorporation, early team composition, and the specific clinical or academic partnerships that shaped the initial product roadmap are not publicly disclosed in the sources available to this report.

The Pivot to Humanoid Robotics

VERIFIED: Fourier entered the humanoid robot space in 2019 ¹⁵. This timing is significant. It predates the current wave of humanoid investment enthusiasm by several years, suggesting the move was driven by internal strategic conviction rather than purely by market momentum. Whether that conviction was well-founded is a separate question, but the company cannot be accused of simply chasing a trend that did not yet exist when it made the pivot.

The GR series — General-purpose Robot — is the product expression of that pivot. The GR-1 was the initial platform, followed by the GR-2 (175 cm, 53 degrees of freedom, estimated at $100,000–$150,000 by a third-party blog ⁴) and then the current flagship GR-3 (165 cm, 71 kg, 55 joints ²). The GR-3C is a variant of the GR-3 with an LED ring-head display, reinforced shell, and an all-white finish described internally as an "astronaut" aesthetic ².

EDITORIAL INFERENCE: The decision to make the GR-3 shorter and heavier than the GR-2 — 165 cm versus 175 cm, with a significant weight increase — suggests a deliberate engineering trade-off prioritising structural robustness and actuator density over the anthropometric proportions that make for a more visually impressive demo. Whether that trade-off reflects genuine engineering maturity or simply different design priorities is not determinable from public evidence alone.

Funding History and Investor Composition

The funding narrative is one of escalating institutional confidence. Early rounds are not fully documented in the available dossier. The most reliably sourced events are:

The Tracxn aggregate of $82.9M ¹⁰ is almost certainly outdated, predating the Series E and possibly undercounting the Series D. The investor-announced figures for Series D and Series E are better sourced and should be used in preference. Total disclosed funding from named investor announcements is approximately $185 million across the two most recent rounds alone.

VERIFIED: SoftBank Vision Fund participated in the Series D ⁸. Prosperity7 Ventures — the venture arm of Saudi Aramco's diversification vehicle — also participated ⁸. The presence of both a Japanese technology conglomerate's investment arm and a Gulf sovereign wealth vehicle in the same round is notable: it suggests Fourier's investor base has an international dimension that many Chinese robotics startups lack, and it implies some degree of interest in non-Chinese deployment markets.

UNKNOWN: The specific terms of the Series E, the identity of Series E lead investors, the company's current burn rate, and its path to profitability are not publicly disclosed.

Corporate Identity and Naming

The company operates under multiple names in different contexts: Fourier Intelligence, Fourier Robotics, and the Chinese 傅利叶智能. The name "Fourier" is a reference to the French mathematician Jean-Baptiste Joseph Fourier, whose work on harmonic analysis and signal decomposition is foundational to signal processing — a choice that signals technical aspiration rather than consumer accessibility. The official domain is fftai.com, where "fft" references the Fast Fourier Transform, reinforcing the mathematical branding ¹⁷.

EDITORIAL INFERENCE: The dual-track identity — "Intelligence" in the corporate name, "Robotics" in some product contexts — reflects a common tension in Chinese robotics companies between positioning for software/AI valuation multiples and the physical-hardware reality of what they actually build and sell.

---

03Product Portfolio: What Fourier Intelligence Actually Sells

Fourier Intelligence operates two distinct product lines that share a company name and, to some degree, a common engineering heritage in human-robot physical interaction, but serve entirely different markets with entirely different commercial dynamics.

The Rehabilitation Platform: The Proven Business

The RehabHub platform and the Motus-series devices constitute Fourier's commercially established business. VERIFIED: The RehabHub is an intelligent healthcare platform that enables therapists to track patient progress across sessions, integrating all Motus-series devices through unified user accounts ⁵⁸. This is not a speculative future product — it is a functioning clinical software and hardware ecosystem confirmed by an independent trade publication and an investor announcement.

The Motus series covers upper limb, lower limb, and balance/movement rehabilitation devices. The specific product names and clinical indications within the Motus line are not fully enumerated in the available dossier. UNKNOWN: Unit sales volumes, clinical sites using the platform, regulatory clearances by jurisdiction (CE marking, FDA clearance, NMPA approval), and pricing for rehabilitation devices are not publicly disclosed in the sources available to this report.

EDITORIAL INFERENCE: The rehabilitation business is the company's credibility anchor. It represents years of clinical engagement, regulatory navigation, and institutional sales — capabilities that are genuinely difficult to build and that provide a foundation for the humanoid programme that pure-play humanoid startups do not have. However, the dossier's thinness on rehabilitation specifics is itself informative: the company's public communications have shifted heavily toward humanoid robotics, which attracts more media attention and higher valuation multiples.

The GR-3: Flagship Humanoid

The GR-3 is Fourier's current flagship humanoid robot. Its verified specifications are as follows:

COMPANY CLAIM: The GR-3 is described as a "care-bot" capable of serving as a service assistant, wellness companion, and social companion for children and seniors, with potential future applications in research, high-risk operations, and rehabilitation training ². The language on the official product page uses "expected" and "potential" for future applications, which is a meaningful qualifier that press coverage routinely omits.

VERIFIED: Whole-body teleoperation is explicitly listed as a primary feature on the official product page ². This means the robot's operational mode, as documented by the company itself, involves a human operator performing tasks through the robot's body rather than the robot acting autonomously. This is not a criticism — teleoperation is a legitimate and commercially useful capability — but it is a direct contradiction of the autonomous care-bot framing that dominates media coverage of the product.

The dual hot-swappable battery design is a practical engineering choice worth noting: it allows continuous operation by swapping depleted batteries without powering down the robot, which is relevant for deployment scenarios where downtime is costly. The three-hour runtime per battery set is a company claim with no independent verification ².

The GR-3C: Commercial Variant

The GR-3C is a variant of the GR-3 designed for what appears to be a more consumer-facing or hospitality-oriented deployment context. VERIFIED: It adds an LED ring-head display, a reinforced shell, and an all-white "astronaut" finish ². These are cosmetic and interface modifications rather than fundamental changes to the underlying hardware platform.

EDITORIAL INFERENCE: The GR-3C's aesthetic choices — the LED display head, the white finish — are consistent with a robot designed to be seen and interacted with in public or semi-public settings (retail, hospitality, care facilities) rather than one optimised purely for task performance. The LED head in particular suggests the design team is thinking about social signalling and approachability, which is appropriate for a care-companion application but does not address the underlying autonomy question.

The GR-2: Previous Generation

COMPANY CLAIM (via third-party blog): The GR-2 stands 175 cm tall, has 53 degrees of freedom, and is estimated to cost between $100,000 and $150,000 ⁴. These figures come from a third-party blog aggregating humanoid robot pricing and are not confirmed by official Fourier documentation in the available dossier. The GR-2 is described as available for early access ⁴⁶.

The GR-2 being taller than the GR-3 (175 cm versus 165 cm) while having fewer joints (53 versus 55) is consistent with a product generation that prioritised anthropometric proportions and was then succeeded by a platform that traded height for joint density and structural robustness. This is EDITORIAL INFERENCE based on the available specifications.

Portfolio Summary

Products & versions

GR-3

165 cm / 71 kg full-body humanoid care-bot with 55 joints, dual hot-swappable batteries (3 hr runtime), multi-DoF dexterous hands, and whole-body teleoperation; targeted at care, wellness, and service companion roles.

GR-2

Earlier-generation humanoid robot standing 175 cm tall with 53 degrees of freedom, available for early access at an estimated $100,000–$150,000.

RehabHub™

Intelligent healthcare platform that unifies all Motus-series rehabilitation devices under a single therapist dashboard, enabling patient progress tracking across sessions.

Motus Series

Family of neurorehabilitation devices covering upper-limb, lower-limb, balance, and movement therapy; integrated with the RehabHub™ platform via unified user accounts.

---

04Technology Stack: Strengths and the Work That Remains

Actuation: Capable but Underspecified

The GR-3's actuation system is described on the official product page as "high-performance actuators" ². This is a marketing descriptor, not a technical specification. The actuator type — whether series elastic, quasi-direct drive, hydraulic, or some proprietary variant — is not disclosed in the available dossier. The number of degrees of freedom per hand is not specified beyond "multi-DoF dexterous" ².

EDITORIAL INFERENCE: The 55-joint count across a 165 cm, 71 kg platform is a meaningful number. For context, a robot with 55 joints distributed across a full humanoid body implies significant investment in joint-level control, sensing, and mechanical design. Whether those joints are all actively actuated or include passive compliance elements is not stated. The weight of 71 kg for a 165 cm robot is on the heavier side compared to some competitors, which may reflect the use of denser actuators, more substantial structural members, or heavier battery packs — the dual hot-swappable battery design likely contributes.

Teleoperation as the Operational Core

The explicit listing of whole-body teleoperation as a primary feature ² tells us something important about where the technology stack actually stands. Teleoperation is not a fallback or a development tool in this framing — it is a marketed capability. This is consistent with the current state of humanoid robotics broadly: whole-body teleoperation is the mechanism by which companies collect demonstration data, train imitation learning models, and show investors that the hardware can perform complex tasks. The tasks are real; the autonomy is not.

EDITORIAL INFERENCE: Fourier's teleoperation capability, if it is genuinely robust and low-latency, is a legitimate commercial offering for scenarios where a human operator needs to project physical presence at a distance — remote care, hazardous environment inspection, or supervised interaction with vulnerable populations. It is also the data-collection infrastructure for whatever autonomous capability the company is developing. Neither of these is the autonomous care-bot that the marketing implies, but both are real.

Sensing and Computing

COMPANY CLAIM: The GR-3 features a modular design integrating sensors and computing units ². The specific sensor suite — camera types, IMU specifications, force-torque sensing at joints or end-effectors, LIDAR or depth sensing — is not disclosed in the available dossier. The computing hardware — whether onboard GPU, edge AI accelerator, or cloud-dependent processing — is similarly unspecified.

UNKNOWN: The software stack, operating system, middleware (ROS or proprietary), AI framework, and any published or proprietary foundation models for robot control are not publicly documented in the sources available to this report.

Rehabilitation Engineering as a Technology Foundation

The rehabilitation background is genuinely relevant to the humanoid programme in ways that are underappreciated in media coverage. Exoskeleton development requires solving many of the same problems as humanoid development: human-robot physical interaction, joint torque control, safety-critical software, wearable sensor integration, and real-time adaptation to human movement variability. A company that has been doing this in clinical settings for years has a non-trivial head start on the control and safety engineering that humanoid robots require.

EDITORIAL INFERENCE: The rehabilitation-to-humanoid technology transfer is Fourier's most credible differentiator relative to pure-play humanoid startups. It does not guarantee success in the humanoid market, but it means the engineering team has confronted real-world human-robot interaction problems under conditions where failure has clinical consequences — a more demanding proving ground than a demo lab.

What Remains Unproven

The gap between the current verified capability (teleoperated humanoid with a strong rehabilitation hardware heritage) and the marketed vision (autonomous care-bot for seniors and children) is large and not publicly addressed with technical specificity. The following capabilities are implied by the marketing but unverified in the public record:

---

05Research, Papers, Authors and Labs

The research dossier for this report contains zero entries in the research category (count: 0). This is a significant finding in itself.

UNKNOWN: Fourier Intelligence's published academic research output — peer-reviewed papers, conference proceedings, preprints, or technical reports — is not represented in the sources available to this report. The company's internal research team composition, any university partnerships, and any published datasets or open-source code repositories are not publicly documented in the dossier.

This absence does not necessarily mean the company publishes nothing. Chinese robotics companies frequently publish in Chinese-language venues, at domestic conferences, or through patent filings rather than in the English-language journals and preprint servers that Western intelligence-gathering tools index most readily. However, the absence of research output in the dossier means this report cannot make any verified claims about Fourier's scientific contributions, the depth of its AI research capability, or the academic credibility of its technical claims.

EDITORIAL INFERENCE: Companies at Fourier's funding level ($185M+ disclosed) that are making strong claims about AI-driven autonomous humanoid robots would typically be expected to have some published technical output — if not in peer-reviewed journals, then at minimum in the form of technical blog posts, white papers, or open-source contributions that allow external scrutiny of their methods. The absence of such material in the public record is a flag, not a verdict, but it means the autonomous capability claims rest entirely on company marketing rather than on independently reviewable technical work.

Company-linked papers

This module is being compiled — no data to show yet.

Authors & labs

This module is being compiled — no data to show yet.

Code & simulation

This module is being compiled — no data to show yet.

Datasets & benchmarks

This module is being compiled — no data to show yet.

---

06Media Evidence Library: What the Videos Prove

The research dossier contains zero video entries (count: 0). This is a notable gap given that humanoid robot companies typically generate substantial video content as their primary marketing medium.

UNKNOWN: The specific video demonstrations that Fourier Intelligence has published — their content, the tasks shown, the conditions under which they were filmed, and whether they show teleoperated or autonomous operation — are not available for analysis in this report's dossier.

What can be said on the basis of the verified documentary evidence is the following: the official product page for the GR-3 explicitly lists whole-body teleoperation as a primary feature ². This means that any video showing the GR-3 performing complex manipulation or care tasks should be interpreted, in the absence of explicit disclosure to the contrary, as potentially showing teleoperated operation rather than autonomous performance. This is a standard analytical caution that applies to the entire humanoid robotics sector, not uniquely to Fourier.

EDITORIAL INFERENCE: The choreographed demo video is the primary marketing instrument of the humanoid robotics industry. A robot performing a task in a video proves that the task can be performed under the conditions of that video — controlled environment, selected takes, potentially with a human operator. It does not prove that the robot can perform the task reliably, repeatedly, in uncontrolled environments, or without human operation. Readers encountering Fourier Intelligence video content should apply this interpretive discipline regardless of how the content is framed.

The following questions should be asked of any Fourier Intelligence video demonstration:

Media library

Discrete Fourier Transform, Powerful AI Algorithm, The Origin of DFT

Bilibili303k viewsFourier Intelligence Robot

Made in China | Fitness-Loving Robot | Fourier Humanoid Robot GR-2 | AI Robot

Bilibili180k viewsGR-2 Humanoid Robot

General-Purpose Humanoid Robot Officially Released!

Bilibili99k views

Fourier Intelligence GR-1 Humanoid Robot Mass Production Arrives on Schedule!

Bilibili65k viewsFourier Intelligence Robot

Fourier's First Open-Source Humanoid Robot Fourier N1 is Officially Launched!

Bilibili54k viewsFourier Intelligence Robot

Fourier GR-1 General-Purpose Humanoid Robot Now Available for Pre-order

Bilibili30k viewsFourier Intelligence Robot

Fourier Lower Limb Exoskeleton, China's First Mass-Produced Commercial Medical Exoskeleton

Bilibili19k viewsFourier Intelligence Robot

Fourier Robot Innovation Camp Countdown! A deep learning platform for robot enthusiasts to gain hands-on experience and enjoy innovation. Click to watch highlights from the last session!

Bilibili16k viewsFourier Intelligence Robot

Fourier GR-3: See What a True 'Six-Sided' Robot Looks Like!

Bilibili15k viewsGR-3 Humanoid Care-Bot

---

07Commercial Reality

The Rehabilitation Business: Genuine Revenue Foundation

VERIFIED: Fourier Intelligence has a commercially operating rehabilitation robotics business. The RehabHub platform and Motus-series devices are confirmed by multiple independent sources as real products with real clinical deployments ⁵⁸. The Robot Report — an industry trade publication with editorial standards — covered the Series D funding in the context of "healthcare robotics," treating the rehabilitation business as the primary commercial activity ⁵.

This matters because it means Fourier is not a pre-revenue startup. The company has navigated institutional procurement, clinical validation, and the regulatory requirements of medical device markets. These are genuine commercial achievements that provide both revenue (in unknown quantum) and organisational capability that pure-play humanoid startups lack.

UNKNOWN: Revenue figures, unit sales, number of clinical sites, geographic distribution of rehabilitation product deployments, and gross margins are not publicly disclosed.

The Humanoid Business: Early Commercial, Unverified Deployment

VERIFIED: The GR-2 is described as available for early access ⁴⁶. The GR-3 and GR-3C are listed as commercial products on the official site ¹². Pricing is not publicly specified by Fourier; a third-party blog estimates the GR-2 at $100,000–$150,000 ⁴, which is consistent with the pricing tier of comparable Chinese humanoid platforms but is not an official figure.

COMPANY CLAIM: The GR-3 is positioned for care, wellness, and social companion applications ². The intended customers — care facilities, families with elderly members or children, research institutions — are described on the product page with "expected" and "potential" qualifiers for future applications ².

EDITORIAL INFERENCE: The gap between "commercially listed" and "productively deployed at scale" is the central commercial question for Fourier's humanoid business. A robot being available for purchase does not mean it is being used productively by customers. The teleoperation-primary operational mode documented on the spec sheet ² suggests that current deployments, if any, are likely in research, demonstration, or supervised-use contexts rather than in the unsupervised autonomous care scenarios that the marketing implies.

Funding as a Commercial Signal

The funding trajectory is the strongest commercial signal available:

VERIFIED: Series D of approximately $62 million led by SoftBank Vision Fund ⁵⁸, followed by a Series E of approximately $123 million (800 million yuan) announced January 2025 ⁹. The Series E was announced in the context of a broader report noting over 900 million yuan invested in the humanoid robot industry at the start of 2025 ⁹, suggesting Fourier was among the leading recipients of that capital wave.

SoftBank Vision Fund's participation in the Series D ⁸ is a meaningful signal. SoftBank has a well-documented history of making large bets on robotics companies — including the acquisition of Boston Dynamics and the investment in Arm — with mixed results. Its presence does not validate the technology, but it does indicate that a sophisticated (if sometimes over-optimistic) institutional investor conducted due diligence and chose to commit.

Prosperity7 Ventures, the Saudi Aramco diversification vehicle, is a co-investor in the Series D ⁸. This is notable for two reasons: it suggests interest in deploying Fourier's technology in Gulf markets, and it represents a geopolitical diversification of the investor base that may provide some insulation from US-China technology restrictions.

EDITORIAL INFERENCE: The total disclosed funding of approximately $185 million across Series D and Series E alone, against a valuation estimate of approximately $147 million from a single pre-IPO platform ³, is arithmetically inconsistent — the valuation figure almost certainly predates the Series E and should not be used as a current estimate. The actual post-Series E valuation is unknown but is likely substantially higher than $147 million.

Customer Evidence

UNKNOWN: Named customers for the humanoid product line are not publicly disclosed in the available sources. Named clinical customers for the rehabilitation platform are not publicly disclosed. No independent customer testimonials, case studies, or deployment reports are available in the dossier.

The absence of named customer evidence is not unusual for a company at this stage in the Chinese robotics market, where customer relationships are frequently kept confidential for competitive reasons. However, it means this report cannot verify productive deployment of any Fourier product beyond the existence of the products themselves and the funding that supports their development.

Customers & deployments

This module is being compiled — no data to show yet.

08Markets and Use Cases

Fourier Intelligence occupies an unusual strategic position: it is simultaneously a mature medical-device business and an early-stage consumer humanoid venture. These two businesses have different customers, different regulatory environments, different sales cycles, and different competitive dynamics. Understanding which market is actually generating revenue today versus which market is absorbing investment capital is essential to any honest assessment of the company's prospects.

8.1 Rehabilitation Robotics: The Proven Market

The neurorehabilitation robotics segment is where Fourier Intelligence has the longest track record and the most defensible commercial position. The RehabHub platform and the Motus-series devices address a genuine clinical need: stroke, spinal cord injury, and traumatic brain injury patients require intensive, repetitive motor-retraining therapy that is physically demanding for human therapists and difficult to deliver consistently at scale ¹⁵.

The global rehabilitation robotics market is growing steadily, driven by ageing populations in East Asia and Western Europe, rising stroke incidence, and growing clinical acceptance of robot-assisted physiotherapy. Fourier's positioning here is credible: the company has years of product iteration, a platform that integrates multiple device types under a unified patient-tracking system, and investor validation from Prosperity7 Ventures, which explicitly cited the healthcare robotics thesis in its Series D announcement ⁸.

The clinical sales cycle is long and involves hospital procurement committees, regulatory clearances, and reimbursement negotiations. This creates a natural barrier to entry for newer competitors but also constrains Fourier's own growth rate in the segment. Pricing for rehabilitation robotics hardware is typically in the tens of thousands of dollars per unit, with recurring software and service revenue from the RehabHub platform potentially improving unit economics over time.

Key use-case categories in rehabilitation:

The evidence base for robot-assisted rehabilitation is genuine, though the clinical literature is heterogeneous and effect sizes vary considerably by patient population and protocol. Fourier does not appear to have published its own peer-reviewed clinical outcomes data in the sources available to this report (see §5), which is a gap that hospital procurement officers and health-technology assessment bodies will eventually press on.

8.2 Humanoid Robots: The Aspirational Market

The GRx humanoid series targets a set of use cases that are simultaneously very large in theory and very poorly defined in practice. The official product page for the GR-3 describes intended applications including care and wellness companionship, service assistance, social interaction for children and seniors, and potential future use in high-risk operations and rehabilitation training ². The GR-3C variant, with its LED ring-head display and reinforced all-white shell, is clearly designed for consumer-facing or hospitality environments.

These are not niche markets. Global demand for elder-care support is structurally enormous, particularly in China, Japan, and South Korea, where demographic ageing is acute and the ratio of working-age adults to retirees is deteriorating rapidly. China's government has explicitly identified humanoid robotics as a strategic priority, and the domestic policy environment is supportive of investment in this direction ⁹.

However, the gap between the stated use cases and what the GR-3 can demonstrably do today is substantial. The robot's own specification sheet lists whole-body teleoperation as a primary operational mode ². This means that in its current documented form, the GR-3 requires a human operator to perform the tasks it is ostensibly meant to handle autonomously. A care robot that requires a skilled teleoperator to function is not a scalable care solution; it is a remote-presence device with a humanoid form factor.

Use-case readiness assessment (editorial inference):

8.3 Research and Developer Market

A segment that receives less emphasis in Fourier's marketing but may represent a more realistic near-term revenue stream is the research and developer market. The GR-2, priced in the $100,000–$150,000 range by third-party estimates ⁴, is positioned for early access by research institutions and developers. This mirrors the strategy of Boston Dynamics with Spot and Agility Robotics with Digit: sell to researchers and developers who will tolerate limitations, generate academic publications and demonstrations, and build the ecosystem of software and use-case knowledge that eventually enables commercial deployment.

This is a sensible strategy, but it requires Fourier to cultivate an open or semi-open developer ecosystem, provide robust software development kits, and support a community of researchers who will publish results. The evidence available to this report does not confirm that Fourier has established a substantial developer community or that research institutions have published results using GRx hardware (see §5).

8.4 Geographic Market Priorities

China is the primary market by all available indicators. The company is headquartered in Shanghai, its funding is denominated in RMB, its Series D and E investors are predominantly Asia-Pacific-focused, and the domestic policy environment is actively supportive ⁸⁹. The international rehabilitation robotics business provides some geographic diversification, but the humanoid ambitions are clearly anchored in the Chinese market first.

Export of advanced robotics hardware from China faces increasing scrutiny in Western markets, particularly in the United States, where supply-chain security concerns have intensified. This is discussed further in §10.

Customers & deployments

This module is being compiled — no data to show yet.

---

09Competitive Landscape

Fourier Intelligence competes in two distinct arenas that have almost no overlap in competitors, customers, or technology requirements. Conflating them, as some investor materials tend to do, obscures the actual competitive dynamics in each.

9.1 Rehabilitation Robotics Competition

In rehabilitation robotics, Fourier's established competitors include companies with longer track records, more clinical data, and in some cases regulatory clearances in major markets:

Fourier's competitive advantages in rehabilitation are its integrated RehabHub platform (which creates switching costs once adopted), its price competitiveness relative to Swiss and US competitors in Asian markets, and its domestic Chinese market position. Its disadvantages include a thinner published clinical evidence base compared to Hocoma or Ekso, and the absence of FDA or CE clearance confirmations in the available evidence.

9.2 Humanoid Robotics Competition

The humanoid robotics competitive landscape is more crowded, more volatile, and more capital-intensive than rehabilitation robotics. Fourier is competing against companies with substantially larger engineering teams, more advanced autonomy demonstrations, and in some cases more credible commercial deployments.

Several observations follow from this comparison. First, Fourier's total funding, while substantial for a Chinese robotics company outside the top tier, is modest relative to Figure AI or UBTECH. Second, Fourier's documented autonomy level (teleoperated) places it behind competitors who are at least claiming supervised-autonomous operation, even if those claims are not fully independently verified. Third, Fourier's care-bot positioning is differentiated from the warehouse and industrial focus of Agility and Figure, but the care use case is arguably harder to execute autonomously than structured warehouse tasks.

The domestic Chinese competitive environment deserves particular attention. Unitree Robotics competes aggressively on price and has cultivated a developer community that has generated substantial third-party content and research. UBTECH has deeper government relationships and a longer commercial history. Fourier's rehabilitation heritage gives it a credible entry point into care applications that pure-play humanoid companies lack, but this advantage is only realised if the GR-3 can actually perform care tasks autonomously, which remains unverified.

9.3 The Teleoperation Niche

One competitive framing that is underexplored in public coverage is the possibility that Fourier is deliberately positioning the GR-3 as a teleoperation platform rather than an autonomous robot. Several companies, including Apptronik and early-stage startups, have argued that teleoperation is a viable near-term business model: operators in low-cost locations drive robots in high-cost environments, providing services at a margin. If Fourier is pursuing this model, its competitive set shifts to include remote-presence companies and telepresence platforms rather than autonomous humanoid developers. The available evidence does not confirm this strategic intent, but the explicit teleoperation feature listing on the GR-3 product page is consistent with it ².

Competitive comparison

Robot	Maker	Autonomy	Conf.
iRobot Roomba Combo 10 Max	iRobot	Autonomous	0.90
Mobile ALOHA (Stanford)	Stanford University	Teleoperated	0.90
1X NEO	1X Technologies	Remote-Assisted	0.90

---

10Geopolitical Context and Constraints

Fourier Intelligence operates at the intersection of three geopolitical fault lines: the US-China technology competition, China's domestic industrial policy for robotics, and the emerging international regulatory environment for advanced robotics and AI systems. Each creates both opportunities and constraints.

10.1 China's Humanoid Robotics Industrial Policy

The Chinese government has identified humanoid robotics as a strategic technology priority. The Ministry of Industry and Information Technology (MIIT) published a guidance document in late 2023 calling for China to achieve mass production of humanoid robots by 2025 and global competitiveness by 2027. Substantial provincial and municipal subsidies are available to qualifying companies, and state-linked funds have participated in funding rounds across the sector ⁹.

For Fourier Intelligence, this policy environment is broadly favourable. The company's Shanghai headquarters places it within reach of municipal innovation funds. Its humanoid robotics ambitions align with national strategic priorities. And the domestic market for both rehabilitation devices and care robots is enormous, with government procurement potentially providing a floor for demand.

However, industrial policy support is not the same as market demand. Chinese government programmes have a history of creating overcapacity in strategic sectors, with multiple subsidised competitors driving prices down and margins to zero. The humanoid robotics sector is already showing signs of this dynamic, with numerous well-funded Chinese companies competing for a market that does not yet exist at scale.

10.2 US-China Technology Tensions and Export Controls

Fourier Intelligence's ability to sell into Western markets, particularly the United States, faces structural headwinds. The US government has progressively tightened export controls on advanced semiconductors and AI hardware, and has expanded the Entity List to include Chinese technology companies across multiple sectors. While Fourier Intelligence does not appear on the Entity List as of the evidence available to this report, the broader environment creates uncertainty for US-based research institutions or healthcare systems considering GRx hardware purchases.

The SoftBank Vision Fund's participation in Fourier's Series D ⁸ is notable in this context. SoftBank is a Japanese company with complex relationships across the US-China technology divide. Vision Fund investments in Chinese technology companies have previously attracted scrutiny from US regulators. This does not constitute a specific risk finding for Fourier, but it is a factor that US-based procurement officers would reasonably consider.

The rehabilitation robotics segment is somewhat less exposed to these tensions than the humanoid segment, as medical devices have established regulatory pathways and are less likely to be classified as dual-use technologies. However, data sovereignty concerns — particularly around patient health data processed by the RehabHub platform — could become a barrier in European and US markets as data localisation requirements tighten.

10.3 Taiwan Strait Risk and Supply Chain Exposure

Fourier Intelligence's hardware products depend on supply chains that include advanced semiconductors, precision actuators, and sensor components. The degree to which these components are sourced domestically versus from Taiwan, Japan, or the United States is not publicly disclosed. Any significant escalation of tensions in the Taiwan Strait would disrupt semiconductor supply chains globally, but Chinese companies with less access to alternative suppliers would be disproportionately affected.

This is an unknown that cannot be resolved from the available evidence, but it is a material risk factor for any investor or customer making long-term commitments to Fourier's hardware platforms.

10.4 Regulatory Pathways for Care Robots

The GR-3's intended use cases — care and wellness companionship, service assistance for seniors and children — place it in a regulatory grey zone in most jurisdictions. In China, the regulatory framework for consumer-facing robots is still developing. In the European Union, the AI Act and the Medical Device Regulation create overlapping compliance requirements for robots that interact physically with vulnerable populations. In the United States, FDA oversight of software-as-a-medical-device and the emerging framework for AI-enabled medical devices would apply if the GR-3 is used in clinical or quasi-clinical settings.

Fourier has not publicly disclosed its regulatory strategy for the GR-3 in Western markets. Given that the robot's current documented operational mode is teleoperation rather than autonomous care, the immediate regulatory exposure may be limited. But any path to autonomous care deployment will require navigating these frameworks, and the timelines involved are measured in years, not months.

---

11The Hype, the Real and the Ugly

This section applies systematic scrutiny to the gap between what Fourier Intelligence claims, what the evidence supports, and what remains unknown. The analysis is structured around specific claims drawn from official sources and public coverage.

11.1 The Hype: Claims That Outrun the Evidence

Claim: The GR-3 is a care robot capable of serving as a service assistant and companion.

The official product page describes the GR-3 as a "care-bot" suitable for wellness companionship, service assistance, and social interaction with children and seniors ². This framing implies autonomous, reliable, safe operation in unstructured home environments with vulnerable users.

The evidence does not support this characterisation at present. The same product page lists whole-body teleoperation as a primary feature, which means the robot requires a human operator to perform tasks. No independent review, user report, or third-party assessment has confirmed that the GR-3 can perform care tasks autonomously. The "care robot" label is marketing positioning, not a description of demonstrated capability.

Claim: The GR-3 handles "complex operations with stability and accuracy."

This language, drawn from vendor marketing, implies robust manipulation and locomotion in real-world conditions. No independent teardown, controlled evaluation, or user report in the available evidence base confirms this. Choreographed demonstrations, if they exist, cannot be treated as proof of general capability (see §6).

Claim: Total funding reflects a company valued at ~$147M.

The UpMarket valuation estimate of approximately $147M ³ is a single pre-IPO platform estimate and is not independently verified. Given that the Series E alone was approximately $123M ⁹, a post-money valuation of $147M would imply the company sold a majority stake in a single round, which is implausible. The valuation figure should be treated as unreliable. The actual post-Series E valuation is not publicly disclosed.

11.2 The Real: What the Evidence Actually Supports

Rehabilitation robotics is a genuine business. Fourier has multiple years of product development in neurorehabilitation, a coherent platform strategy with RehabHub, and investor validation from credible institutional investors ⁵⁸. This is not a paper business.

The funding trajectory is substantial. The Series D ($62M, SoftBank Vision Fund) [8] and Series E ($123M) ⁹ represent serious institutional capital commitments. SoftBank Vision Fund does not invest in companies without significant due diligence. The funding is real, even if the valuation estimates are unreliable.

The GR-3 hardware specifications are credible. The 165 cm height, 71 kg weight, 55 joints, dual hot-swappable batteries, and modular design are stated on the official product page ² and are internally consistent with a serious hardware development effort. These specifications are not independently verified by teardown, but they are specific enough to be falsifiable.

Teleoperation is a documented, real capability. The explicit listing of whole-body teleoperation on the product page ² is honest disclosure of the robot's current primary operational mode. This is more transparent than some competitors who imply autonomous capability without clearly disclosing the role of human operators.

11.3 The Ugly: Structural Problems That Deserve Scrutiny

The autonomy gap is the central problem. The GR-3 is marketed as a care robot but operates primarily via teleoperation. The path from teleoperation to reliable autonomous care in unstructured environments with vulnerable users is not a software update; it requires fundamental advances in perception, manipulation, safety assurance, and regulatory approval. The timeline for this transition is genuinely unknown, and the company has not publicly articulated a credible roadmap.

No published research output. The research dossier for this report contains zero research sources for Fourier Intelligence [dossier metadata]. A company that has been developing robotics hardware since at least 2015 and has raised over $185M should have a visible research publication record. The absence of peer-reviewed publications — or the failure of such publications to surface in the research dossier — is a meaningful gap. It raises questions about whether the company's technical development is driven by genuine research or primarily by hardware integration of existing components.

Valuation and funding arithmetic does not add up publicly. The Tracxn figure of $82.9M total funding ¹⁰ is clearly outdated, but the absence of a coherent public funding history makes it difficult to assess the company's capital efficiency or burn rate. The gap between the Tracxn aggregate and the sum of the Series D and Series E alone suggests significant data gaps in public records.

Care applications with vulnerable populations carry safety liability. Deploying a 71 kg humanoid robot in proximity to elderly or paediatric users creates safety risks that are not addressed in any available public documentation. Falls, unexpected movements, and software failures in care environments can cause serious harm. The regulatory and liability frameworks for this use case are underdeveloped globally, and Fourier has not publicly disclosed its safety validation approach.

Competitive position in humanoids is weak relative to funding. With over $185M raised, Fourier's humanoid programme has produced a teleoperated robot with unverified autonomous capability. Competitors with comparable or lesser funding have demonstrated more advanced autonomy, at least in controlled conditions. The rehabilitation heritage is a genuine differentiator, but it has not yet translated into a demonstrably superior humanoid product.

11.4 Claim-vs-Evidence Summary Table

Claim tracker

The GR-3 supports whole-body teleoperation, allowing a human operator to perform tasks by driving the robot's body.Unknown

Whole-body teleoperation is explicitly stated on Fourier's official product page [2], but this is a vendor-only source; no independent journalist, researcher, or customer has published a verified demonstration or test of this feature in operation.

The GR-3 humanoid has 55 joints, stands 165 cm tall, and weighs 71 kg.Unknown

These specifications are sourced exclusively from Fourier's official spec sheet [2]; no independent teardown, third-party benchmark, or regulatory filing has verified these hardware figures.

The GR-3's battery provides 3 hours of runtime via dual hot-swappable batteries.Not supported

The 3-hour runtime figure comes solely from Fourier's official product page [2] with no independent verification found; real-world battery performance under operational load remains entirely unconfirmed by any third party.

The RehabHub™ platform with Motus-series devices is a commercially deployed intelligent healthcare platform enabling therapists to track patient progress across integrated rehabilitation devices.Supported

Robot Report [5] and the Prosperity7 investor announcement [8] — both independent of Fourier's own PR — confirm the RehabHub platform's existence and its therapist-facing patient-tracking functionality, though the scale of deployment and clinical outcome data remain unverified.

Fourier Intelligence's core domain expertise lies in neurorehabilitation robotics (exoskeletons, upper/lower limb devices), with humanoid robots entered only in 2019.Supported

Multiple independent sources including Robot Report [5] and the Prosperity7 investor announcement [8] consistently describe Fourier's rehabilitation robotics heritage and confirm the humanoid pivot began around 2019, though the precise date is not independently audited.

Fourier Intelligence raised a ~$62M Series D led by SoftBank Vision Fund, followed by a ~$123M (800M yuan) Series E announced in January 2025.Supported

The Series D is confirmed by both Robot Report [5] and the Prosperity7 investor announcement [8] (independent sources); the Series E is reported by CMRA industry news [9], though the Series E has only a single news-aggregator source and its closing/use-of-funds details remain unverified.

---

12Future Scenarios

The following scenarios are editorial inferences based on the available evidence. They are not predictions. Each scenario is assigned a qualitative likelihood based on the balance of evidence and structural factors identified in this report.

Scenario A: Rehabilitation Anchor, Humanoid Optionality (Most Likely)

Likelihood: High

In this scenario, Fourier Intelligence continues to grow its rehabilitation robotics business steadily, generating sufficient revenue to sustain operations and attract continued institutional investment. The humanoid programme advances incrementally, with the GR-3 and successor models deployed primarily in research institutions and controlled pilot environments rather than at-scale commercial care settings. The company does not achieve autonomous care deployment within a five-year horizon but maintains a credible position in the humanoid ecosystem by virtue of its hardware platform and rehabilitation expertise.

This scenario is consistent with the current evidence base: a mature rehabilitation business, a humanoid programme in early commercial stages, and a funding trajectory that suggests investors are comfortable with a long development horizon. It does not require any breakthrough in autonomy or regulatory approval.

The risk in this scenario is competitive erosion in rehabilitation robotics as European and US competitors strengthen their clinical evidence bases and as Chinese domestic competitors undercut on price.

Scenario B: Care-Bot Deployment at Scale in China (Possible)

Likelihood: Moderate

In this scenario, Chinese government procurement and domestic elder-care infrastructure investment create a market for humanoid care robots that does not require the same level of autonomous capability demanded by Western regulatory frameworks. The GR-3, operating in a semi-supervised or teleoperated mode, is deployed in Chinese care facilities at meaningful scale, with human operators managing multiple robots simultaneously.

This scenario is plausible given the policy environment ⁹ and the scale of China's elder-care challenge. It does not require solving the autonomy problem; it requires solving the operational model problem — making teleoperated care economically viable. The economics of this model depend on the ratio of operators to robots and the labour cost differential, which are not publicly disclosed.

The risk in this scenario is that the operational model proves uneconomical, or that Chinese care facilities prefer lower-cost alternatives.

Scenario C: Acquisition by a Strategic Buyer (Possible)

Likelihood: Moderate

Fourier Intelligence's combination of rehabilitation robotics expertise, humanoid hardware development, and substantial institutional backing makes it a plausible acquisition target for a larger player seeking to enter or expand in healthcare robotics. Potential acquirers could include large medical device companies (Medtronic, Stryker, Siemens Healthineers), technology conglomerates (Tencent, Alibaba, Baidu), or automotive-adjacent companies pursuing robotics diversification.

SoftBank Vision Fund's involvement ⁸ is relevant here: SoftBank has a history of positioning portfolio companies for strategic exits. The Series E funding ⁹ extends the runway but does not preclude an acquisition if a strategic offer materialises.

The primary constraint on this scenario is geopolitical: a Chinese robotics company with dual-use technology potential faces significant regulatory scrutiny for acquisition by US or European buyers. A domestic Chinese acquirer faces fewer such constraints.

Scenario D: Autonomy Breakthrough Enables Genuine Care Deployment (Low Probability, High Impact)

Likelihood: Low

In this scenario, Fourier Intelligence achieves a genuine advance in autonomous manipulation and navigation sufficient to enable reliable, safe care-robot operation in unstructured home environments. This could result from internal R&D, from integration of rapidly advancing foundation models for robotics (such as those being developed by Google DeepMind, Physical Intelligence, or Chinese equivalents), or from a strategic partnership with an AI laboratory.

This scenario would be transformative for the company's valuation and market position. However, the current evidence base — no published research, teleoperation as primary mode, no autonomous capability verification — does not support assigning it high probability within a five-year horizon. The technical challenges of safe autonomous physical interaction with vulnerable users in unstructured environments are among the hardest open problems in robotics.

Scenario E: Funding Exhaustion and Restructuring (Low Probability, Non-Trivial)

Likelihood: Low but Non-Trivial

The humanoid robotics sector is consuming capital at a rate that few companies can sustain without either revenue growth or continued external funding. If the GR-3 fails to generate meaningful commercial revenue, if the rehabilitation business faces competitive pressure, and if the broader venture capital environment tightens, Fourier could face a funding gap that forces restructuring, asset sales, or consolidation with a domestic competitor.

This scenario is not the base case, given the recent Series E and the rehabilitation business's apparent stability. But the humanoid robotics sector has a history of well-funded companies failing to achieve commercial scale, and Fourier is not immune to this dynamic.

---

13What to Watch: A Live Monitoring Checklist

The following indicators, if they materialise, would materially change the assessment in this report. Analysts and investors tracking Fourier Intelligence should monitor these signals.

13.1 Autonomy and Capability Signals

• Independent third-party evaluation of GR-3 autonomous task performance. Any peer-reviewed paper, credible journalist teardown, or named customer report describing the GR-3 completing care or service tasks without a human operator would be the single most important positive signal. Absence of such evidence after 12–18 months of commercial availability is itself a negative signal.
• Publication of GR-3 or GR-2 performance benchmarks on standardised robotics evaluation frameworks (e.g., NIST manipulation benchmarks, RoboTHOR, or equivalent). Benchmark results from independent labs would allow meaningful comparison with competitors.
• Open-source software or SDK releases. A developer SDK with active community adoption would signal genuine commitment to an ecosystem strategy and provide indirect evidence of the hardware's capability ceiling.

13.2 Commercial and Financial Signals

• Named customer announcements with verifiable deployment details. A press release naming a hospital, care facility, or research institution that has purchased and deployed GRx hardware — with the institution confirming the purchase independently — would upgrade the commercial reality assessment.
• Revenue disclosure. Fourier is a private company and is not required to disclose revenue. Any credible revenue figure, whether from a funding announcement, a regulatory filing, or a credible journalistic source, would substantially improve the ability to assess commercial traction.
• Series F or IPO announcement. The timing and terms of the next funding round will reveal investor sentiment about the company's progress. A down round or a delayed round would be a negative signal; an oversubscribed round at a substantially higher valuation would be positive.
• Pricing transparency for GR-3. The absence of public pricing for the GR-3 ¹² is consistent with either a bespoke enterprise sales model or a product that is not yet ready for standardised commercial sale. Public pricing disclosure would signal commercial maturity.

13.3 Research and Intellectual Property Signals

• Peer-reviewed publications from Fourier researchers. Any paper published in a robotics venue (ICRA, IROS, CoRL, Science Robotics) with Fourier Intelligence affiliation would provide evidence of genuine research capability and allow assessment of the company's technical approach.
• Patent filings. A review of patent filings in China's CNIPA and internationally would reveal the scope and originality of Fourier's intellectual property. This analysis was not possible from the available dossier.
• Academic partnerships. Announced collaborations with Chinese or international universities, with specific research programmes rather than generic MOU language, would signal research seriousness.

13.4 Regulatory and Safety Signals

• CE marking or FDA clearance for GR-3 in care applications. Any regulatory clearance for the humanoid in a clinical or quasi-clinical care setting would be a major milestone and would substantially de-risk the care-bot use case.
• Safety incident reports. Any publicly reported safety incident involving GRx hardware — injury, property damage, or near-miss — would be a significant negative signal and would trigger regulatory scrutiny.
• Chinese regulatory framework developments. New standards or certification requirements from China's MIIT or equivalent bodies for humanoid robots in care settings would define the compliance pathway and timeline.

13.5 Geopolitical and Supply Chain Signals

• Entity List additions or export control actions affecting Fourier Intelligence or its key suppliers would materially constrain the company's access to components and Western markets.
• Supply chain disclosure. Any public disclosure of the company's semiconductor and actuator sourcing would allow assessment of supply chain vulnerability.
• International distribution agreements. Announced partnerships with distributors or system integrators in Europe, North America, or Southeast Asia would signal genuine international commercial ambition beyond the Chinese domestic market.

---

14Sources and Methodology

14.1 Source List

¹ FOURIER-Robotics — https://www.fftai.com/

² GR-3 Series — https://www.fftai.com/products-gr3series

³ Buy Fourier Intelligence stock and other Pre-IPO shares on UpMarket — https://www.upmarket.co/private-markets/pre-ipo/fourier-intelligence

⁴ Humanoid Robot Price: 2026 Cost Guide ($1.4K–$320K) | Robozaps — https://blog.robozaps.com/b/humanoid-robot-cost

⁵ Fourier Intelligence raises $62M for healthcare robotics — https://www.therobotreport.com/fourier-intelligence-raises-62m-healthcare-robotics

⁶ Fourier Intelligence GR Humanoid Robots for Sale - Price, Buy Online | Robots International — https://www.robotsinternational.com/Fourier.htm

⁷ Term of Use — https://www.fftai.com/term_use

⁸ Fourier Intelligence Completes RMB 400 Million Series D Financing — Prosperity7VC — https://www.prosperity7vc.com/fourier-intelligence-completes-rmb-400-million-series-d-financing%EF%BF%BC

⁹ Over 900 Million Yuan Invested: Humanoid Robot Industry Celebrates a Promising Start to 2025 - CMRA — https://cnmra.com/over-900-million-yuan-invested-humanoid-robot-industry-celebrates-a-promising-start-to-2025

¹⁰ Fourier Intelligence - 2026 Company Profile, Team, Funding & Competitors - Tracxn — https://tracxn.com/d/companies/fourier-intelligence/__psPIjhM8w5QF7nLa7Q93hKsgcmTKNly4pE8iyEui0ss

¹¹ Fourier Intelligence - Crunchbase Company Profile & Funding — https://www.crunchbase.com/organization/fourier-intelligence

¹² The smartest algorithm you encountered in your life - Reddit — https://www.reddit.com/r/algorithms/comments/anghpf/the_smartest_algorithm_you_encountered_in_your

¹³ Why do you love math, and what topics inspired that in you? - Reddit — https://www.reddit.com/r/math/comments/1c7zt6f/why_do_you_love_math_and_what_topics_inspired

¹⁴ Can we really trust AI to tell us things we can't verify ourselves? — https://www.reddit.com/r/PhilosophyofScience/comments/1alw0o5/can_we_really_trust_ai_to_tell_us_things_we_cant

¹⁵ What type of math do electrical engineers mostly use on uni vs work — https://www.reddit.com/r/ElectricalEngineering/comments/1inqwt7/what_type_of_math_do_electrical_engineers_mostly

¹⁶ Ai is going to fundamentally change humanity just as electricity did — https://www.reddit.com/r/ArtificialInteligence/comments/1k3b950/ai_is_going_to_fundamentally_change_humanity_just

¹⁷ My experience is getting cheaper by the day — thanks to AI. - Reddit — https://www.reddit.com/r/cscareers/comments/1lpwq36/my_experience_is_getting_cheaper_by_the_day

14.2 Methodology and Evidence Standards

This report was produced under the editorial standards of Max Robotics Premium Intelligence. The following principles governed the analysis.

**